Consideration of spatial companion biomarkers for targeted therapeutics in cancer: depatuxizumab mafodotin in glioblastoma.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 41632538.
- Also identified by DOI 10.1172/jci.insight.198475 and PMC identifier 13043081.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
An expanded access program of depatuxizumab mafodotin for patients with progressive glioblastoma explores the relationship between tumor EGFR expression and outcomes.
Medical subject headings
- Glioblastoma
- Antibodies, Monoclonal, Humanized
- Brain Neoplasms
- Biomarkers, Tumor